Rebalancing the Immune System with Transformative, Next-Generation Treatments
Champlain Bio is advancing next-generation therapies designed to rebalance the immune system. Our programs target key mechanisms that drive disease, including autoantibody production in autoimmune conditions and protein aggregation disorders.
Our pipeline includes three novel treatment approaches with the potential to meaningfully improve patients’ lives. Through scientific rigor and innovative technology, we are building disease-modifying therapies aimed at delivering durable, real-world impact.
Rebalancing the Immune System
At Champlain Bio, we go beyond symptom management. Our lead therapy targets monoclonal antibodies, leading to long-term disease modification.
Restoring Immune Balance
We aim to improve long-term patient outcomes.
Developing Next-Generation Therapies
Targeting the root causes of autoimmune diseases, not just the symptoms.
Addressing Unmet Need
Focused on the high-risk relapse population with no current effective therapies.
Demonstrating Preclinical Success
Our therapy has demonstrated strong preclinical data, showing significant promise for autoimmune diseases.
Leading the Way with Groundbreaking Science
Champlain Bio’s scientific foundation is built on our proprietary monoclonal antibody. Through advanced research and preclinical studies, we are advancing next-generation therapies to target immune system dysregulation and modify disease progression.
Visionary Leaders with Proven Track Records in Biotech
Champlain Bio’s leadership team brings decades of experience in biotech, drug development, and commercialization. Together, we’ve founded multiple companies, advanced groundbreaking therapeutics, and delivered substantial value to investors.
Michael Spector
Co-founder
Robyn Hunter
Susan Sobolov
Co-founder
Financial advisor
